MedPath

Circulating Innate Lymphoid Cell Type 2 (ILC2) Levels and Asthma: a Case-control Study

Completed
Conditions
Asthma
Interventions
Biological: ILC2 levels in blood
Registration Number
NCT03128762
Lead Sponsor
University Hospital, Montpellier
Brief Summary

The primary objective of this study is to demonstrate differences in ILC2 blood levels between asthma patients and control patients.

Detailed Description

The secondary objectives of this study are:

To show that ILC2 levels differ between asthma patients with a "TH2" (helper T cell type 2) profile and asthma patients with a "non-TH2" profile. A TH2 profile is defined as (for a given patient):

* circulating eosinophils \> 500 mm\^3 at least once during the year AND

* positive allergy skin or specific IgE (Immunoglobulin E) test AND

* induced sputum eosinophil level \>3% of leukocytes AND

* exhaled nitric oxide \> 25 ppb.

To study the variation in ILC2 levels over time among asthma patients who obtained a good level of control compared to other patients. A good level of control is defined as:

* no exacerbations during 6 months of followup (an exacerbation is defined as the un-planned need for care that modifies the patient's prescription for \>48h)

* FEV1 (forced expiratory volume in 1 second) value current / FEV1 best value \> 0.8

* symptom levels correspond to an ACQ (Asthma Control Questionnaire) questionnaire score of \< 0.75 over the last 7 days

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CasesILC2 levels in bloodPatients in this group are asthmatic (see inclusion/exclusion) criteria. Intervention: ILC2 levels in blood
ControlsILC2 levels in bloodControls are non-asthmatic subjects that are age and gender matched to asthma cases. Intervention: ILC2 levels in blood
Primary Outcome Measures
NameTimeMethod
% ILC2 cells among total blood lymphocytesDay 0

Determined by flow cytometry

Secondary Outcome Measures
NameTimeMethod
% ILC2 cells among total blood lymphocytes6 months

Determined by flow cytometry; Asthma patients only.

© Copyright 2025. All Rights Reserved by MedPath